Brief: Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B
23/07/2019 13:40
July 23 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM ACHIEVES FIFTY PERCENT ENROLLMENT IN THE PIVOTAL
PHASE
3 SIERRA TRIAL FOR IOMAB-B
* ACTINIUM - SIERRA TRIAL HAS YIELDED PROMISING PRELIMINARY
FEASIBILITY AND SAFETY DATA THAT WERE PRESENTED AT ASH 2018, TCT
2019 AND ASCO 2019
Source text for Eikon: ID:nPn5ZdPCwa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities